Emerging treatments

Neuroplasticity modulating strategies

Nervous system stimulation (central, peripheral, and mixed) utilizing transcutaneous, epidural, or magnetic approaches allows for motor and nonmotor neuronal activation to be used in the context of therapeutic interventions.[114][115][116]

Acute hypoxia

Acute intermittent hypoxia has been consistently shown to improve function in patients with incomplete motor injuries.[117]

Transplantation strategies

The transplantation of several cell types has been investigated as potential therapy for spinal cord injury (SCI); these include Schwann cells, neural stem cells or progenitor cells, olfactory ensheathing cells, oligodendrocyte precursor cells, and mesenchymal stem cells. Strategies are focused on neuroprotection, immunomodulation, and neural reconstruction.[118][119] However, despite demonstration of safety and effectiveness in animal models, sufficient evidence of efficacy in a clinical setting is still lacking.[119]

Chondroitinase ABC

Studies in animals revealed that chondroitinase-induced plasticity improved the dexterity associated with trained skills, but had adverse effects on nontrained motor activities.[120][121] There are no studies in humans at this time.

Electrical stimulation

Simultaneous chemical and electrical stimulation of receptors has a synergistic effect. This has led to the development of combined electrical and pharmacologic strategies for improving locomotor function.[122][123] Preliminary results from a trial of combined locomotor treadmill training, weight support, and epidural electrical stimulation showed an increase in voluntary movement among participants.[124] One systematic review concluded that functional electrical stimulation cycling exercise improves lower-body muscle health in adults with SCI, and may increase power output and aerobic fitness.[125] Cranial electrotherapy stimulation improved pain intensity and pain interference with daily life, with few side effects, in patients with SCI.[126]

Botulinum toxin

Preliminary evidence indicates that botulinum toxin type A (known as onabotulinumtoxinA, incabotulinumtoxinA, or abobotulinumtoxinA in the US) may reduce intractable chronic neuropathic pain in patients with SCI. Further study is warranted, given the difficulty of treating neuropathic pain.[127][128][129]

Use of this content is subject to our disclaimer